WALTHAM, Mass., April 28, 2026

Affinia Therapeutics has announced new progress for AFTX-201, its lead investigational gene therapy for BAG3-associated Dilated Cardiomyopathy (DCM), ahead of presentations at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting. The company will present new preclinical data, the design of its Phase 1/2 UPBEAT clinical trial, and advances in its proprietary AAV capsid engineering and high-yield manufacturing platform, reinforcing its position in next-generation cardiovascular gene therapy development.

AFTX-201 Shows Strong Potential in BAG3-Associated DCM

AFTX-201 is being developed as a potential best-in-class one-time intravenous gene therapy for patients with BAG3-associated DCM, a serious inherited cardiovascular disease with limited treatment options. The therapy is designed to deliver a fully human, full-length BAG3 transgene using Affinia’s proprietary engineered capsid that enables highly efficient cardiac transduction at doses 5 to 10 times lower than conventional AAV platforms such as AAV9 and AAVrh74. This lower-dose strategy may significantly improve both safety and treatment efficiency.

Preclinical studies showed that AFTX-201 successfully increased BAG3 protein levels in the heart and fully restored cardiac function in animal models of BAG3 DCM. These findings support its potential to address the genetic root cause of the disease rather than simply managing symptoms, positioning the therapy as a potentially curative treatment.

Strong Regulatory Momentum Supports Clinical Advancement

Advertisement

cGxPJobs Banner

Affinia has already achieved major regulatory milestones in 2026. The U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application for AFTX-201 and granted the therapy Fast Track designation, accelerating its development pathway. Additionally, the European Medicines Agency (EMA) granted Orphan Drug designation, while Health Canada approved the Clinical Trial Application for the UPBEAT Phase 1/2 clinical trial.

The UPBEAT study is designed to evaluate the safety and efficacy of AFTX-201 in patients living with BAG3-associated DCM. As a simple one-time IV administration, the therapy offers significant convenience and long-term disease management advantages compared to chronic standard-of-care treatments.

Expanding Platform Innovation Beyond Cardiovascular Disease

At ASGCT 2026, Affinia will also showcase its broader gene therapy platform through additional poster presentations focused on analytical product development, central nervous system delivery, and next-generation AAV engineering. The company will present new data validating ATC-134, its novel blood-brain barrier-penetrant AAV capsid, which demonstrated widespread CNS expression in over 90% of neurons after IV dosing in nonhuman primates.

Additionally, Affinia will present preclinical data from its collaboration with Modalis Therapeutics, targeting Myotonic Dystrophy Type 1, further expanding its pipeline beyond cardiovascular disease into rare neurological disorders.

With strong preclinical efficacy, accelerated regulatory support, and scalable manufacturing innovation, Affinia Therapeutics is building a differentiated leadership position in precision gene therapy. As AFTX-201 advances through the UPBEAT trial, the company is moving closer to delivering a potentially transformative treatment for patients suffering from devastating inherited heart disease.

Source: Affinia Therapeutics press release